Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymphoblastic leukemia (B-ALL)], lymphomas, small lung cell carcinoma (SCLC), sarcomas, and others.
将
水溶性N
DA交联剂脲多莫司汀(BO-1055)用于治疗癌症的方法,该癌症选自各种类型的人类白血病[如急性髓性白血病(ALL)和急性B淋巴细胞白血病(B-ALL)]、淋巴瘤、小肺细胞癌(SCLC)、肉瘤等。